Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
前收盘价
US$99.60
+US$1.11 · +1.13%
盘前
US$99.79
+US$0.19 · +0.19%
10月12日 7:00 ET
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
83
深度低估
情绪
72
看涨
风险
31
中等风险
动量
38
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
日内区间
当前US$99.60
52周区间
当前US$99.60
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 443.28亿 USD | 419.5亿 USD | 401.09亿 USD | 436.53亿 USD | 430.75亿 USD |
| 销货成本 | 197.21亿 USD | 206.25亿 USD | 200.72亿 USD | 213.3亿 USD | 198.61亿 USD |
| 毛利 | 246.07亿 USD | 213.25亿 USD | 200.37亿 USD | 223.23亿 USD | 232.14亿 USD |
| 研究与开发 | 29.55亿 USD | 28.23亿 USD | 27.19亿 USD | 28.52亿 USD | 27.38亿 USD |
| 销售、一般及管理费用 | 123.78亿 USD | 116.51亿 USD | 108.83亿 USD | 111.09亿 USD | 112.76亿 USD |
| 营业费用 | 165.86亿 USD | 144.74亿 USD | 136.02亿 USD | 139.61亿 USD | 140.14亿 USD |
| 利息收入 | 2.3亿 USD | 3.44亿 USD | 3.85亿 USD | 1.83亿 USD | 4300万 USD |
| 利息支出 | 3.41亿 USD | 6.03亿 USD | 6.98亿 USD | 3.15亿 USD | 4.1亿 USD |
| 折旧和摊销 | 31.16亿 USD | 32.18亿 USD | 32.43亿 USD | 32.67亿 USD | 35.38亿 USD |
| 营业利润 | 80.48亿 USD | 68.25亿 USD | 64.35亿 USD | 83.62亿 USD | 92亿 USD |
| 净利润 | 65.24亿 USD | 134.02亿 USD | 57.23亿 USD | 69.33亿 USD | 70.71亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。